Total Reports
21
Below-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Akbash Dog (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Akbash Dog, no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Akbash Dog ranks #359 of 510 by total reports (21). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Akbash Dog has 21 reports now versus 20 in that prior snapshot: 1 more (5.0%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Akbash Dog changesTotal Reports
21
Below-median volume
Deaths Reported
2
of 21 reports
Death-coded share of reports
9.5%
9.5% death-coded
Avg Age at Report
4.9 yr
44.6 kg avg weight
9.5% of 21 akbash dog reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2014 | 1 | |
| 2015 | 1 | |
| 2017 | 3 | |
| 2018 | 2 | |
| 2019 | 2 | |
| 2020 | 2 | |
| 2021 | 2 | |
| 2022 | 2 | |
| 2023 | 2 | |
| 2024 | 1 | |
| 2025 | 2 | |
| 2026 | 1 | |
Signature read: 21 reports place Akbash Dog in the lower third of breed filing volume (#359 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Akbash Dog sits at #359 of 510 by report volume among all breeds and #233 of 298 among dog breeds, with 21 reports and 2 (9.5%) death-coded. Mean age at report: 4.9 years, average weight 44.6 kg (98.3 lbs).
Top reported signs: Lack of efficacy (ectoparasite) - flea (3), Vomiting (3), Diarrhoea (2). Most-referenced drug: Oclacitinib Maleate (2 reports), followed by Fluralaner Chew Tablets (2) and Milbemycin Oxime + Spinosad (2).
Outcome coding on 21 status-recorded reports is dominated by Outcome Unknown (38.1%). Annual submissions ranged 1-2,026 across 12 years on file.
Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.
Sparse-volume peer sets for Akbash Dog drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds by reported average weight (44.6 kg here).
What to do with this dog
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →